A case report about recurrent BRAF V600E-mutant adult gliomas [41] found that after a failure of a BRAF inhibitor alone, a BRAF inhibitor combined with a MEK inhibitor could exert a markedly prolonging OS. This evidence concerns the gene BRAF and central nervous system cancer.